147 results on '"Orfi, L"'
Search Results
2. In vitro and cellular study of benzothiophene- 3-carboxamides as inhibitors of Aurora kinase family: SW04.S16–159
3. Characterization of p53 activator compounds which inhibit a survival factor kinase as well: P06-143
4. The antiproliferative effect of known and novel PLK1 inhibitors on different cancer cell lines: B2.08
5. Biochemical characterization of novel PKD1 inhibitors using kinase assays and cellular studies: B2.09
6. Biochemical characterization of novel EGFR and c-Met single and dual inhibitors: B2.07
7. Screening a kinase inhibitor library for multiple target inhibitors of VEGFR2 and PDGFRb: B2.06
8. Targeting of the VEGF-kinase inhibitor PTK787 to angiogenic vasculature using RGD-equipped albumin carrier molecules
9. Comparison of measured and calculated lipophilicity of substituted aurones and related compounds
10. Novel members of quinoline compound family enhance insulin secretion in RIN-5AH beta cells and in rat pancreatic islet microtissue
11. Protein kinase Cζ drives Sphingomyelin Metabolism in the Nucleus during Cell Proliferation
12. Rational Design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium
13. 801: Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors − suggestion of combination therapy
14. 791: Investigation of the mode of action of sunitinib kinase inhibitor profile analogues in insulin release
15. Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors
16. Protein Kinase C ζ Drives Sphingomyelin Metabolism in the Nucleus During Cell Proliferation
17. Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing
18. Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing
19. Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology
20. Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology
21. Rational Design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium
22. Novel, Selective CDK9 Inhibitors for the Treatment of HIV Infection
23. ChemInform Abstract: Nitrogen Bridgehead Compounds. Part 85. Synthesis and Reactivity of 3, 4-Dihydro-1H,6H-(1,4)oxazino(3,4-b)quinazolin-6-ones.
24. Signalling Inhibitors Against Mycobacterium tuberculosis – Early Days of a New Therapeutic Concept in Tuberculosis
25. Structure – Activity Relationships of PDE5 Inhibitors (Supporting Material)
26. Prediction Oriented QSAR Modelling of EGFR Inhibition
27. Reliability of logP Predictions Based on Calculated Molecular Descriptors: A Critical Review
28. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
29. Protein Kinase Cξ Drives Sphingomyelin Metabolism in the Nucleus During Cell Proliferation
30. Inhibition of c-Met with the Specific Small Molecule Tyrosine Kinase Inhibitor SU11274 Decreases Growth and Metastasis Formation of Experimental Human Melanoma
31. Acid−Base Profiling of Imatinib (Gleevec) and Its Fragments
32. Heterocondensed quinazolones: synthesis and protein-tyrosine kinase inhibitory activity of 3,4-dihydro-1H, 6H-[1,4]oxazino[3,4-b]quinazolin-6-one derivatives
33. Kinase inhibitors reduce 7,12-dimethylbenz[a]anthracene-induced oncosuppressor gene expression in short-term experiments,Inibitori delle chinasi riducono l'espressione genica dell'onco-soppressore indotto da 7,12- dimethylbenz[a]anthracene in esperimenti a breve termine
34. Tyrosine kinase inhibitors - Small molecular weight compounds Inhibiting EGFR
35. Pulsed field gradient nmr spectroscopic analysis of peptide-micelle interactions
36. Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors
37. Flk-1 as a target for tumor growth inhibition
38. ChemInform Abstract: Nitrogen Bridgehead Compounds. Part 85. Synthesis and Reactivity of 3, 4-Dihydro-1H,6H-(1,4)oxazino(3,4-b)quinazolin-6-ones.
39. HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models.
40. Lyophilization and homogenization of biological samples improves reproducibility and reduces standard deviation in molecular biology techniques.
41. Author Correction: Mito-oncology agent: fermented extract suppresses the Warburg effect, restores oxidative mitochondrial activity, and inhibits in vivo tumor growth.
42. Mito-oncology agent: fermented extract suppresses the Warburg effect, restores oxidative mitochondrial activity, and inhibits in vivo tumor growth.
43. Regulation of influenza A virus mRNA splicing by CLK1.
44. Machine learning and docking models for Mycobacterium tuberculosis topoisomerase I.
45. Nox4 contributes to the hypoxia-mediated regulation of actin cytoskeleton in cerebrovascular smooth muscle.
46. Development of a 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases.
47. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.
48. Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion.
49. NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling.
50. Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.